Evotec Navigates a Pivotal Year Amidst Restructuring and Profit Pressures

The biotechnology firm Evotec finds itself at a critical juncture. While its recently concluded fiscal year delivered solid revenue, a stark forecast for 2026 has unsettled investors, projecting a potential plunge in operating profit to zero. All eyes are now on the company’s upcoming April 8th report, where management must detail how its radical "Horizon" cost-cutting initiative plans to steer the business back to stability.

A Forecast That Rattled the Market

The primary catalyst for recent share price weakness stems directly from the outlook for the current year. Management has explicitly labeled 2026 a transitional period, anticipating revenues to fall within a range of €700 to €780 million. More alarmingly for investors, the company indicated that adjusted EBITDA could shrink to zero in a worst-case scenario. This guidance came as a severe disappointment; prior analyst consensus had estimated this figure to exceed €80 million. The announcement promptly sent Evotec's shares tumbling to a fresh annual low.

Divergent Performance Across Business Units

Preliminary results for 2025 present a tale of two divisions. At a group level, Evotec met its own expectations, posting revenues of approximately €788 million. Adjusted EBITDA stood at around €41 million. However, a segment breakdown reveals significant underlying strain.

The core drug discovery business contracted by 13%, slipping into an operating loss. Counteracting this decline was the standout performance of the Biologics division. This unit reported a revenue surge of roughly 40%, reaching €259 million, and contributed €53 million to the group’s operating profit.

Should investors sell immediately? Or is it worth buying Evotec?

The "Horizon" Restructuring Plan

In response to these challenges, Evotec's board has launched the comprehensive "Horizon" restructuring program. The plan involves a significant workforce reduction, with up to 800 positions set to be eliminated globally. The company will also consolidate its operational footprint, reducing its number of sites to ten. This includes the complete closure of its Munich location.

These measures will incur one-time costs of about €100 million. Management projects that the savings will begin to materialize in the second half of 2026, with the program expected to yield annual cost reductions of €75 million from the end of 2027 onward.

Strategic Shift and a Cash Injection from Sandoz

Funding this strategic overhaul is facilitated by a major asset sale. Evotec has agreed to sell its Biologics site in Toulouse to Sandoz. The transaction will provide an immediate cash infusion of approximately $350 million, with the potential for over $300 million in additional milestone payments. This move aligns with a strategic pivot toward a less capital-intensive model, with a greater emphasis on monetizing proprietary technologies.

Evotec at a turning point? This analysis reveals what investors need to know now.

This repositioning has attracted notable institutional interest. Goldman Sachs increased its stake to 6.12% in mid-January. Furthermore, investment firms Triton and Mubadala Investment Company each hold more than a five percent share in Evotec. Despite near-term headwinds, the leadership maintains its medium-term ambition: to surpass €1 billion in revenue by 2030.

The upcoming April 8th report is pivotal. Investors await the final audited figures and, crucially, detailed cost breakdowns for the Horizon initiative alongside a firm financial guide for 2026. These details will be the true test of whether the combination of aggressive cost savings and enhanced liquidity from the Toulouse sale can realistically pave the way toward the company's target of a 20% operating margin by 2028.

Ad

Evotec Stock: New Analysis - 30 March

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

DE0005664809 | EVOTEC | boerse | 69027588 |